MARKET

APVO

APVO

Aptevo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.25
-0.44
-5.72%
Closed 16:00 09/23 EDT
OPEN
7.74
PREV CLOSE
7.69
HIGH
7.92
LOW
7.13
VOLUME
32.38K
TURNOVER
--
52 WEEK HIGH
11.73
52 WEEK LOW
2.940
MARKET CAP
23.44M
P/E (TTM)
-0.6503
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial
Trial Advancing on Schedule and Second Patient Dosed in Cohort 7 No Evidence of Drug-Induced Anti-Drug Antibodies Observed to Date SEATTLE, WA / ACCESSWIRE / September 1, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO),
Benzinga · 09/01 13:04
Aptevo Therapeutics EPS beats by $0.02, beats on revenue
Aptevo Therapeutics (APVO): Q2 GAAP EPS of -$2.10 beats by $0.02.Revenue of $0.47M beats by $0.28M.Cash, equivalents, and short-term investments of $10.2MPress Release
Seekingalpha · 08/14 13:28
Aptevo Therapeutics Q2 EPS $(2.10) Down From $(0.30) YoY, Sales $473.00K Down From $7.36M YoY
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(2.10) per share. This is a 600 percent decrease over losses of $(0.30) per share from the same period last year. The company reported $473.00 thousand in
Benzinga · 08/14 13:14
Aptevo Therapeutics to sell its RUXIENCE and IXINITY royalty and milestone payments
Aptevo Therapeutics (APVO +1.9%) has engaged Piper Sandler to sell its RUXIENCE and IXINITY royalty streams and milestone payments. As announced in June, A
seekingalpha · 07/21 19:08
All You Need to Know About Aptevo Therapeutics Inc. (APVO) Rating Upgrade to Buy
Zacks · 06/30 17:00
Has Aptevo Therapeutics (APVO) Outpaced Other Medical Stocks This Year?
Zacks · 06/30 16:30
Aptevo Therapeutics collects $0.75M working capital escrow
Seeking Alpha - Article · 06/29 13:51
Aptevo collects $750K payment from sale of hemophilia therapy
Seeking Alpha - Article · 06/29 13:51
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APVO. Analyze the recent business situations of Aptevo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APVO stock price target is 35.00 with a high estimate of 42.00 and a low estimate of 31.00.
EPS
Institutional Holdings
Institutions: 56
Institutional Holdings: 8.56M
% Owned: 264.93%
Shares Outstanding: 3.23M
TypeInstitutionsShares
Increased
6
58.18K
New
9
90.91K
Decreased
6
2.93K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About APVO
Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)) and VARIZIG (Varicella Zoster Immune Globulin (Human)).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aptevo Therapeutics Inc stock information, including NASDAQ:APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.